[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-loss":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,52,82,115,152,178,201,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100579121","phase-4-tranexamic-acid-for-second-trimester-dilation-and-evacuation-and-bleeding-outcomes-100579121",false,"NCT06820177","Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes","Prophylactic Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Able to understand and sign informed consent\n* Speaks English or Spanish language,\n* Requesting pregnancy termination or procedural management of fetal demise - Intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation\n\nExclusion Criteria:\n\n* History of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism)\n* History of coagulopathy\n* Anticoagulant use in the preceding five days\n* Severe renal impairment\n* Chorioamnionitis or sepsis\n* Suspected placenta accreta spectrum\n* Prophylactic uterotonics other than oxytocin given (or planned to be given) at the start of the D\\&E\n* Known allergic reaction or hypersensitivity to TXA",true,"FEMALE","18 Years",{"count":20,"type":21},276,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth. Some guidelines are recommending the use of TXA for both the prevention and management of bleeding for abortion care. However, there are currently no published studies assessing the association between TXA and bleeding outcomes for abortion procedures. This study will involve a randomized, placebo-controlled trial of pregnant patients aged 18 and older desiring dilation and evacuation (D\\&E) for abortion or fetal demise at 18-24 weeks gestation. The primary aim is to determine whether prophylactic TXA has an effect on the need for additional interventions to control bleeding at the time of D\\&E. The secondary aim is to determine whether prophylactic TXA has an effect on the mean quantitative procedural blood loss.",[27,28,29,30,31],"Abortion","Dilation and Evacuation","Hemorrhage","Prophylactic Tranexamic Acid Use","Blood Loss",[33,34,35,36,37,38],"abortion","dilation and evacuation","TXA","hemorrhage","Tranexamic acid","D&E","RECRUITING","2026-06-12",{"date":42,"type":43},"2026-06-15","ACTUAL",{"date":45,"type":43},"2025-04-22",{"date":47,"type":21},"2027-05",{"name":49,"class":50},"University of California, San Diego","OTHER",3,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100633409","reducing-blood-loss-during-myomectomyuterine-artery-ligation-vs-pericervical-tourniquet-100633409","NCT07526311","Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical Tourniquet","Bilateral Uterine Artery Ligation Versus Pericervical Mechanical Tourniquet Application in Reducing Intraoperative Blood Loss During Transabdominal Myomectomy.","* Inclusion Criteria:\n\n  * Female participants aged 25 to 48 years\n  * Body mass index less than 35 kg\u002Fm²\n  * Symptomatic uterine myomas requiring surgical treatment\n  * Intramural myomas classified as FIGO types 3 to 6\n  * Diagnosis confirmed by transvaginal ultrasound and\u002For magnetic resonance imaging\n  * Maximum diameter of the largest myoma 20 cm or less\n  * Scheduled for elective transabdominal myomectomy\n  * Able and willing to provide written informed consent\n* Exclusion Criteria:\n\n  * Submucosal, intracavitary, pedunculated subserosal, cervical, or adnexal myomas\n  * FIGO types 0, 1, 2, 7, or 8 myomas\n  * History of pelvic inflammatory disease or peritonitis\n  * Previous abdominal or pelvic surgery for non-obstetric causes\n  * Previous uterine surgery\n  * Use of hormonal therapy within the previous 3 months\n  * Known bleeding disorder\n  * Use of anticoagulant or antiplatelet therapy\n  * Preoperative hemoglobin less than 10 g\u002FdL\n  * Body mass index 35 kg\u002Fm² or greater\n  * Intraoperative conversion from myomectomy to hysterectomy","25 Years","48 Years",{"count":62,"type":21},40,[64],"NA","The goal of this clinical trial is to compare two surgical techniques for reducing blood loss during transabdominal myomectomy in women with symptomatic uterine fibroids. The main question it aims to answer is whether bilateral uterine artery ligation reduces intraoperative blood loss more effectively than pericervical mechanical tourniquet application, without increasing operative complications. Researchers will compare bilateral uterine artery ligation with pericervical mechanical tourniquet application during open myomectomy to evaluate blood loss and surgical safety. Participants will undergo elective transabdominal myomectomy and will be randomly assigned to one of the two vascular control techniques before myoma enucleation.",[67,31],"Myoma;Uterus",[69,70,71,72],"uterine artery ligation","peri cervical mechanical tourniquet","blood loss","myomectomy","2026-04-10",{"date":75,"type":43},"2026-04-13",{"date":73,"type":21},{"date":78,"type":21},"2027-04-10",{"name":80,"class":50},"Cairo University",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100476785","phase-2-oxytocin-pharmacokinetics-and-pharmacodynamics-100476785","NCT05488457","Oxytocin Pharmacokinetics and Pharmacodynamics","Pharmacokinetics and Pharmacodynamics of Oxytocin in Cesarean Delivery","Inclusion Criteria\n\n* 18-50 years old\n* intrauterine pregnancy\n* term (\\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy\n* non-emergent (scheduled or unscheduled) cesarean delivery\n\nExclusion Criteria:\n\n* allergy or contraindication to oxytocin\n* inability to provide informed consent","50 Years",{"count":91,"type":21},100,[93],"PHASE2","Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynamics of all plasma oxytocin to see how concentrations correspond to the contractile effect on the uterus.\n\nAfter delivery of the fetus, study subjects will receive a bolus of IV deuterated oxytocin followed by an unlabeled oxytocin infusion. Venous blood samples drawn at multiple time points (within 1 hour after delivery) will be analyzed for plasma concentrations of labeled and unlabeled (endogenous + exogenous infused) oxytocin over time. Plasma concentrations will be compared with 0-10 uterine tone scores measuring uterine contraction strength, to describe the concentration-effect relationship.\n\nThe goal of this study is to define both the pharmacokinetics and pharmacodynamics of oxytocin in parturients to help identify the cause(s) of failed first-line oxytocin therapy.",[96,97,31],"Post Partum Hemorrhage","Cesarean Section Complications",[99,100,101,102,103,104],"Oxytocin","pharmacokinetics and Pharmacodynamics","Uterine Tone","Postpartum","Elective C-Section","Parturients","2025-10-01",{"date":107,"type":43},"2025-10-03",{"date":109,"type":43},"2025-01-01",{"date":111,"type":21},"2027-12-31",{"name":113,"class":50},"University of Chicago",2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":123,"minAge":4,"maxAge":4,"enrollmentInfo":124,"targetDuration":126,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":137,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":81},"100547068","transfusion-surveillance-in-anaesthesia-100547068","NCT06403163","Transfusion Surveillance in Anaesthesia","Biological Transfusion Efficiency Registry Transfusion Surveillance in Anaesthesia","STAR","Inclusion Criteria:\n\n* all patients who have received an hemostasis product\n\nExclusion Criteria:\n\n* patient who refused to consent to data analysis and study participation","ALL",{"count":125,"type":21},50000,"2 Weeks","OBSERVATIONAL","the aim of this register is to collect exhaustively the different data available surrounding a transfusion act in the context of an active haemorrhage. The aim is to allow different modelling and analysis related to emergency transfusion.",[130,131,132,133,134,135,136,31],"Transfusion Reaction","Transfusion Related Complication","Anesthesia","Anesthesia; Shock","Side Effect","Fresh Blood Stool","Blood Coagulation Disorder",[138,139,140,141,142],"transfusion","monitoring","emergency situation","shock","fresh frozen plasma","2025-08-25",{"date":145,"type":43},"2025-09-02",{"date":147,"type":43},"2022-09-01",{"date":149,"type":21},"2030-12-31",{"name":151,"class":50},"Erasme University Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":123,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":81},"100599804","phase-4-the-perioperative-outcome-of-epinephrine-infusion-and-tranexamic-acid-in-knee-arthroplasty-surgery-100599804","NCT07089251","The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery","Inclusion Criteria:\n\n* Patients undergoing knee joint arthroplasty.\n* Saudi and Non-Saudi Patient.\n* Patients who have Complete medical record.\n\nExclusion Criteria:\n\n* End stage renal disease\n* Liver cirrhosis\n* Coagulopathy\n* Pre-operative Hgb \\\u003C10 5.\n* History of cerebrovascular accident or myocardial infarction in past 12 months.\n* History of Heart failure.\n* History of arrhythmia.\n* History of pheochromocytoma, thyrotoxicosis and glaucoma.\n* Pregnancy or breast feeding\n* History of Deep venous thrombosis or pulmonary embolism\n* Allergy to epinephrine or tranexamic acid","70 Years",{"count":160,"type":21},80,[24],"The aim of this clinical trial is to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative blood loss, thromboembolic complications, and hospitalization duration in patients undergoing knee joint arthroplasty.\n\nAlso aim to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative thromboembolic complications, and hospitalization duration",[164,165,166,31,167,168],"Knee Arthroplasty, Total","Knee Arthritis, Osteoarthritis","Total Knee Anthroplasty","Tranexamic Acid Use","Epinephrine","2025-07-21",{"date":171,"type":43},"2025-07-28",{"date":173,"type":43},"2025-07-15",{"date":175,"type":21},"2027-06-24",{"name":177,"class":50},"King Abdullah International Medical Research Center",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":16,"sex":17,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":114},"100420864","local-tranexamic-acid-during-vaginal-hysteractomy-to-reduce-blood-loss-100420864","NCT04760301","Local Tranexamic Acid During Vaginal Hysteractomy to Reduce Blood Loss","Local Tranexamic Acid During Vaginal Hysterectomy to Reduce Blood Loss","Inclusion Criteria:\n\n* 20-90 years old female patients going through vaginal hysterctomy\n\nExclusion Criteria:\n\n* massive bleeding during operation due to major vessles injury\n* known coagulopathies\n* sensitivity to tranexamic acid\n* medical need in tranexamic acid administration during operation due to bleeding","20 Years","90 Years",{"count":188,"type":21},60,[64],"Assessing the efficiency of Prophylactic use of local tranexamic acid during vaginal hysterectomy to reduce blood loss during operation",[31],"2025-05-01",{"date":194,"type":43},"2025-05-06",{"date":196,"type":43},"2021-02-16",{"date":198,"type":21},"2026-06",{"name":200,"class":50},"Meir Medical Center",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":81},"100577790","maternal-fetal-outcomes-of-genital-blood-loss-beyond-18-weeks-of-pregnancy-100577790","NCT06802874","Maternal-fetal Outcomes of Genital Blood Loss Beyond 18 Weeks of Pregnancy","PEG18","Inclusion Criteria:\n\n* Pregnancy beyond 18 weeks gestational age complicated by genital bleeding;\n* Age of the patient ≥18 years;\n* Delivery at the O.U. of Obstetrics and Prenatal Age Medicine\n\nExclusion Criteria:\n\nNone","45 Years",{"count":210,"type":21},300,"The primary objective is to assess in terms of frequency the adverse outcomes (premature birth, maternal-fetal haemorrhage, maternal fetal-neonatal death) of pregnancies of women attending the obstetric-gynaecological emergency department for genital bleeding beyond the 18th week of pregnancy.",[31],[214],"Pregnancy blood loss","2025-01-26",{"date":217,"type":43},"2025-01-31",{"date":219,"type":43},"2023-11-15",{"date":221,"type":21},"2026-12-31",{"name":223,"class":50},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":16,"sex":123,"minAge":4,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":240,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":81},"100519915","d2-versus-d3-dissection-in-laparoscopic-right-hemicolectomy-100519915","NCT06049758","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy In Right Cancer Colon Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with right-side colon cancer (caecum, ascending, or hepatic flexure)\n* Diagnosed by CT entero-colonography\n* Diagnosed by colonoscopy\n* Diagnosed by biopsy.\n\nExclusion Criteria:\n\n* Emergency surgery (obstruction, perforation with generalized peritonitis),\n* Metastatic tumor diagnosed\n* ASA score of IV or higher\n* Need for more than one surgical procedure\n* Conversion to open surgery",{"count":160,"type":21},[64],"Evaluating the differences between D2 and D3 lymphadenectomy in laparoscopic right hemicolectomy in patients with right cancer colon post-operative outcome, intra-operative blood transfusion, post-operative ICU admission, anastomotic leakage, lymph node harvesting in the final specimen, and six months follow up and overall survival time after 5-years",[31,235,236,237,238,239],"Intensive Care","Anastomotic Leakage","Lymph Node Disease","Survival","Blood Transfusion","NOT_YET_RECRUITING","2023-09-19",{"date":243,"type":43},"2023-09-22",{"date":245,"type":21},"2024-01-02",{"date":247,"type":21},"2030-01-02",{"name":249,"class":250},"General Committee of Teaching Hospitals and Institutes, Egypt","OTHER_GOV"]